← Back to Search

Nonsteroidal Anti-inflammatory Drug

Meclofenamate for Brain Cancer

N/A

Waitlist Available

Led By Adrienne Boire, MD, PhD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

There is no limit on the number of brain metastases

Age 18-80

Must not have

Known leptomeningeal metastases

Progressive systemic disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Summary

This trial is testing a drug to see if it can prevent brain metastasis growth. This is the first time the drug is being used to treat brain metastasis, and researchers want to see if it's effective and safe.

Who is the study for?

This trial is for adults aged 18-80 with recurrent or progressive brain metastasis from solid tumors, visible on MRI. Participants must have a stable systemic disease or no evidence of disease and can't be pregnant, have had recent surgery, active bleeding issues, severe allergies to NSAIDs like meclofenamate, certain heart conditions, uncontrolled systemic cancer growth, or poor kidney/liver function.

What is being tested?

The study tests Meclofenamate's effectiveness in preventing new brain metastases in patients whose cancer has spread to the brain. It's a pilot study aimed at seeing if larger trials are feasible and understanding the drug's impact on both the patient and their brain metastasis.

What are the potential side effects?

Potential side effects may include digestive system issues due to Meclofenamate’s properties similar to common pain relievers (NSAIDs). Since it was previously used for pain relief, risks might mirror those associated with NSAID use.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I may have multiple brain metastases.

Select...

I am between 18 and 80 years old.

Select...

I can care for myself but may need occasional help.

Select...

I have at least one growing brain tumor from cancer that started elsewhere, visible on an MRI.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My cancer has spread to the lining of my brain and spinal cord.

Select...

My condition is getting worse over time.

Select...

I have a heart rhythm problem that needs medication or a pacemaker.

Select...

I am being treated for heart failure.

Select...

I do not have an active brain bleed.

Select...

I have not had any bleeding in my stomach or intestines in the last 6 months.

Select...

I am currently on blood thinners.

Select...

I currently have a bleeding disorder.

Select...

My kidney function is low, shown by high creatinine or low clearance.

Select...

I am allergic to certain anti-inflammatory drugs.

Select...

I cannot take medicine by mouth.

Select...

My steroid dose was raised in the last two weeks.

Select...

I am currently on medication to prevent blood clots.

Select...

My cancer originated in the brain.

Select...

I had surgery less than two weeks ago.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Feasible (if at least 50% of patients enrolled are evaluable in brain by MRI at the 2-month timepoint)

Secondary study objectives

Adverse events

Progression free survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: MeclofenamateExperimental Treatment1 Intervention

All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.

0 / 19Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,956 Previous Clinical Trials

595,526 Total Patients Enrolled

Adrienne Boire, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cance Center

Media Library

Meclofenamate (Nonsteroidal Anti-inflammatory Drug) Clinical Trial Eligibility Overview. Trial Name: NCT02429570 — N/A

Brain Metastases Research Study Groups: Meclofenamate

Brain Metastases Clinical Trial 2023: Meclofenamate Highlights & Side Effects. Trial Name: NCT02429570 — N/A

Meclofenamate (Nonsteroidal Anti-inflammatory Drug) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02429570 — N/A

~2 spots leftby Apr 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.